Literature DB >> 21842322

Association between statins given in hospital and mortality in pneumonia patients.

Michael B Rothberg1, Carol Bigelow, Penelope S Pekow, Peter K Lindenauer.   

Abstract

BACKGROUND: Statins are prescribed to lower cholesterol, but also have anti-inflammatory properties. Some observational studies suggest that statins may reduce mortality from sepsis.
METHODS: Using a highly detailed administrative database, we conducted an observational cohort study of all patients aged ≥18 years who received a discharge diagnosis of pneumonia from 2003-2005 at 376 hospitals. Patients with contraindications to statins, and those unable to take oral medications or discharged within 2 days were excluded. We used multivariable logistic regression and propensity matching to compare mortality among patients who did and did not receive statins on hospital day 1 or 2.
RESULTS: Of the 121,254 patients who met the inclusion criteria, median age was 74; 56% were female and 70% were white; 19% received a statin on day 1 or 2. Compared to patients who did not receive statins, statin-treated patients were less likely to be admitted to intensive care (15.7% vs 18.1%, p < 0.001), require mechanical ventilation (6.9% vs. 9.3%, p < 0.001), or die in hospital (3.9% vs 5.7%, p < 0.001). After multivariable adjustment, including the propensity for statin treatment and severity at presentation, mortality was lower in statin-treated patients [OR for propensity-adjusted 0.86 (95% CI 0.79 to 0.93) OR for propensity-matched 0.90, (0.82 to 0.99)]. For patients admitted to intensive care the adjusted odds ratio for mortality with statins was 0.93 (95% CI 0.81 to 1.06), whereas outside intensive care it was 0.79 (95% CI 0.71 to 0.87).
CONCLUSIONS: Inpatient treatment with statins is associated with a modest reduction in pneumonia mortality outside of intensive care.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21842322      PMCID: PMC3286569          DOI: 10.1007/s11606-011-1826-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  23 in total

Review 1.  Sepsis: current status, future prospects.

Authors:  John C Marshall
Journal:  Curr Opin Crit Care       Date:  2004-08       Impact factor: 3.687

2.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

3.  Statin treatment after onset of sepsis in a murine model improves survival.

Authors:  Marc W Merx; Elisa A Liehn; Jürgen Graf; Annette van de Sandt; Maren Schaltenbrand; Jürgen Schrader; Peter Hanrath; Christian Weber
Journal:  Circulation       Date:  2005-07-05       Impact factor: 29.690

Review 4.  Pneumococcal pneumonia: epidemiology and clinical features.

Authors:  T J Marrie
Journal:  Semin Respir Infect       Date:  1999-09

5.  Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality.

Authors:  Gregg C Fonarow; R Scott Wright; Frederick A Spencer; Paul D Fredrick; Wei Dong; Nathan Every; William J French
Journal:  Am J Cardiol       Date:  2005-09-01       Impact factor: 2.778

6.  Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis.

Authors:  H Ando; T Takamura; T Ota; Y Nagai; K Kobayashi
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

7.  Reduction in mortality associated with statin therapy in patients with severe sepsis.

Authors:  Paul P Dobesh; Donald G Klepser; Timothy R McGuire; Craig W Morgan; Keith M Olsen
Journal:  Pharmacotherapy       Date:  2009-06       Impact factor: 4.705

8.  HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis.

Authors:  Marc W Merx; Elisa A Liehn; Uwe Janssens; Rudolf Lütticken; Jürgen Schrader; Peter Hanrath; Christian Weber
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

9.  The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia.

Authors:  Eric M Mortensen; Marcos I Restrepo; Antonio Anzueto; Jacqueline Pugh
Journal:  Respir Res       Date:  2005-07-25

10.  Statin use and risk of community acquired pneumonia in older people: population based case-control study.

Authors:  Sascha Dublin; Michael L Jackson; Jennifer C Nelson; Noel S Weiss; Eric B Larson; Lisa A Jackson
Journal:  BMJ       Date:  2009-06-16
View more
  21 in total

1.  Cholesterol levels, statins, vitamin D, and associated risk of pneumonia.

Authors:  Luca Mascitelli; William B Grant; Mark R Goldstein
Journal:  Eur J Clin Pharmacol       Date:  2011-12-15       Impact factor: 2.953

2.  Statins and sepsis - scientifically interesting but clinically inconsequential.

Authors:  Dean T Eurich; Sumit R Majumdar
Journal:  J Gen Intern Med       Date:  2012-03       Impact factor: 5.128

3.  The effect of statins on the outcome of Clostridium difficile infection in hospitalized patients.

Authors:  A Atamna; D Yahav; N Eliakim-Raz; E Goldberg; H Ben-Zvi; A Barsheshet; A Elis; J Bishara
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-10       Impact factor: 3.267

4.  Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza.

Authors:  Alaa Atamna; Tanya Babitch; Mayaan Bracha; Nadav Sorek; Ben-Zvi Haim; Avishay Elis; Jihad Bishara; Tomer Avni
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-28       Impact factor: 3.267

5.  Statin Use and Hospital Length of Stay Among Adults Hospitalized With Community-acquired Pneumonia.

Authors:  Fiona Havers; Anna M Bramley; Lyn Finelli; Carrie Reed; Wesley H Self; Christopher Trabue; Sherene Fakhran; Robert Balk; D Mark Courtney; Timothy D Girard; Evan J Anderson; Carlos G Grijalva; Kathryn M Edwards; Richard G Wunderink; Seema Jain
Journal:  Clin Infect Dis       Date:  2016-05-10       Impact factor: 9.079

6.  Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice.

Authors:  Yohichi Kumaki; John D Morrey; Dale L Barnard
Journal:  Future Virol       Date:  2012-08       Impact factor: 1.831

7.  HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis.

Authors:  Joel D Mermis; Steven Q Simpson
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 8.  The controversy over H5N1 transmissibility research: an opportunity to define a practical response to a global threat.

Authors:  David S Fedson; Steven M Opal
Journal:  Hum Vaccin Immunother       Date:  2013-02-07       Impact factor: 3.452

9.  Chronic Statin Use and Long-Term Rates of Sepsis: A Population-Based Cohort Study.

Authors:  Henry E Wang; Russell Griffin; Nathan I Shapiro; George Howard; Monika M Safford
Journal:  J Intensive Care Med       Date:  2014-09-15       Impact factor: 3.510

Review 10.  Are there any benefits from statin treatment for the septic patient?

Authors:  Peter S Kruger; Bala Venkatesh
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.